Review: Optimal use of biologics in the management of Crohn’s disease
Crohn’s disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago ha...
Main Authors: | Remo Panaccione MD, FRCPC, Subrata Ghosh MD, FRCP, FRCP(E) |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2010-05-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/1756283X09357579 |
Similar Items
-
Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls
by: Paulo Gustavo Kotze, et al.
Published: (2017-04-01) -
Review: Anti-adhesion molecule therapy for inflammatory bowel disease
by: Subrata Ghosh, et al.
Published: (2010-07-01) -
Review: Efficacy and safety of adalimumab in Crohn's disease
by: Gary R. Lichtenstein, et al.
Published: (2008-07-01) -
The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis
by: Neal Shahidi, et al.
Published: (2016-05-01) -
The old versus the new: which do you keep in postoperative Crohn's disease?
by: Paulo Gustavo Kotze, et al.
Published: (2018-04-01)